circle

INVESTORS & MEDIA

PRESS RELEASES

  • Webcast
    X Q4 2019 Cytokinetics, Inc. Earnings Conference Call
    Mar 3, 2020 4:30 PM EST

    Q4 2019 Cytokinetics, Inc. Earnings Conference Call
    Mar 3, 2020 4:30 PM EST
  • Webcast
    X 31st Annual Piper Jaffray Healthcare Conference
    Dec 4, 2019 1:00 PM EST

    31st Annual Piper Jaffray Healthcare Conference
    Dec 4, 2019 1:00 PM EST
Date Title and Summary
Toggle Summary Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting
Preclinical Studies Demonstrate Distinct Binding Site for Next-Generation Cardiac Myosin Inhibitor SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data related to CK-3773274 (CK-274) were presented at the
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on March 3, 2020
SOUTH SAN FRANCISCO, Calif. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Second Interim Analysis in GALACTIC-HF Expected to Occur in Q1 2020 Topline Results Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the publication of a manuscript relating to the design of GALACTIC-HF ( G
Toggle Summary Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants
Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced the recipients of its Communications Fellowship Grant program, an annual grant program
Toggle Summary Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor Planned to Enter Clinic in 1H 2020 SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.
Toggle Summary Cytokinetics Announces Start of REDWOOD-HCM, a Phase 2 Clinical Trial of CK-3773274
Next-Generation Cardiac Myosin Inhibitor Advances In Clinical Trial Designed to Assess Effects Using Two-Week Dose Titration Schedule SOUTH SAN FRANCISCO, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that REDWOOD-HCM ( R andomized E valuation